Last reviewed · How we verify

LEQVIO — Competitive Intelligence Brief

LEQVIO (LEQVIO) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PCSK9 inhibitor (siRNA). Area: Cardiovascular.

marketed PCSK9 inhibitor (siRNA) PCSK9 mRNA Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

LEQVIO (LEQVIO) — University of Louisville. LEQVIO (inclisiran) reduces LDL cholesterol by inhibiting PCSK9 protein synthesis through RNA interference, allowing more LDL receptors to remain on liver cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LEQVIO TARGET LEQVIO University of Louisville marketed PCSK9 inhibitor (siRNA) PCSK9 mRNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PCSK9 inhibitor (siRNA) class)

  1. University of Louisville · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LEQVIO — Competitive Intelligence Brief. https://druglandscape.com/ci/leqvio. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: